Can You Lose Weight on 1.7mg Wegovy?

Where does 1.7mg actually sit in the dose schedule?

Wegovy's licensed titration path runs 0.25mg, 0.5mg, 1.0mg, 1.7mg, and then 2.4mg, each held for roughly four weeks before the prescriber reviews progress. So 1.7mg is the penultimate step, typically reached around week thirteen of treatment. Some people spend longer here if their prescriber judges it appropriate, either because tolerability calls for it or because the response at this level is already strong.

A common misconception worth clearing up: the earlier doses are not just "placebo" phases you have to survive before the real medicine kicks in. Semaglutide is pharmacologically active at every licensed strength. What increases with the dose is the degree of GLP-1 receptor activation, which, in plain terms, means a stronger brake on appetite and a further slowing of gastric emptying. Weight loss at 1.7mg is entirely plausible; it is not a stepping stone you're meant to sail through without any effect.

For a broader look at how all the Wegovy strengths compare in practice, the Wegovy dose guide on this site walks through each stage. And if you are still in the earlier part of the schedule, there is a detailed look at weight loss at lower Wegovy doses too.

What do the clinical trial data say about weight loss before 2.4mg?

The headline figure from the STEP 1 trial, published in the New England Journal of Medicine, is around 15% average body-weight reduction over 68 weeks at 2.4mg. That final number, though, is the product of a gradual curve that began well before participants reached the top dose.

Semaglutide's mechanism (suppressing appetite through GLP-1 receptor activation) does not switch on only at 2.4mg. By the time someone reaches 1.7mg they have typically been on treatment for three months, and the appetite changes most people describe (smaller portions feeling satisfying, less urge to snack, food feeling less urgent) are already present. Individual responses vary considerably, which is why clinical oversight matters throughout.

The NICE appraisal of Wegovy (TA875) recommends a clinical review at six months on maintenance dose: if weight loss is under 5%, continuing treatment is reconsidered. The implication for people at 1.7mg is that this dose is still part of the escalation period, not the maintenance plateau, so a six-month maintenance review does not apply here, your prescriber monitors progress at each step.

The higher-dose semaglutide picture is also worth understanding if you are thinking about what the end of the titration schedule looks like.

What side effects are most common at this point in treatment?

GI effects (nausea, loose stools, indigestion, and occasional vomiting) are the most frequently reported side effects across all Wegovy doses, and they tend to flare briefly after each dose increase. Moving from 1.0mg to 1.7mg is no exception. For most people these settle within one to two weeks. Staying well hydrated and eating smaller, lower-fat meals during the adjustment period tends to help.

Less common but more serious effects that warrant prompt medical attention include severe stomach pain that travels to the back (a possible sign of pancreatitis), signs of a gallbladder problem, or symptoms of dehydration following significant vomiting or diarrhoea. The NHS semaglutide medicine page sets out the full side-effect picture clearly.

You can report any suspected side effect, including ones not listed in the leaflet, through the MHRA's Yellow Card scheme. It is worth knowing about even if you never need it.

If you are curious about how Wegovy's overall profile compares across doses, the Wegovy treatment overview covers the mechanism and evidence in full.

Should you stay at 1.7mg or push to 2.4mg?

That is genuinely a clinical call, not a personal preference. Some people find 1.7mg well-tolerated and effective enough that their prescriber agrees there is no compelling reason to escalate yet. Others move to 2.4mg on schedule and find the additional appetite reduction valuable. Neither path is universally right.

What you should not do is make the decision alone, either stopping at 1.7mg indefinitely without a review, or skipping ahead to 2.4mg because a forum post suggested it. The titration schedule is not arbitrary: the four-week intervals allow your system to adjust and your prescriber to assess progress properly.

If cost is a factor in your thinking about doses and how long to continue treatment, the Wegovy cost guide gives an honest breakdown of what private treatment involves. And if you are at a much earlier stage and wondering whether anything at all is happening, the 0.5mg question is answered separately.

At nume, a real prescriber reviews your case before every dose change, not software, and not a template decision. If you would like to discuss where you are in your Wegovy journey, speak to our prescribers through a free consultation.